Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics
Open Access
- 9 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4), e0195354
- https://doi.org/10.1371/journal.pone.0195354
Abstract
Over 1.4 million people are diagnosed with colorectal cancer (CRC) each year, making it the third most common cancer in the world. Increased screening and therapeutic modalities including improved combination treatments have reduced CRC mortality, although incidence and mortality rates are still increasing in some areas. Serum-based biomarkers are mainly used for follow-up of cancer, and are ideal due to the ease and minimally invasive nature of sample collection. Unfortunately, CEA and other serum markers have too low sensitivity for screening and preoperative diagnostic purposes. Increasing interest is focused on the possible use of biomarkers for predicting treatment response and prognosis in cancer. In this study, we have performed mass spectrometry analysis (UPLC-UDMSE) of serum samples from 19 CRC patients. Increased levels of C-reactive protein (CRP), which occur during local inflammation and the presence of a systemic inflammatory response, have been linked to poor prognosis in CRC patients. We chose to analyze samples according to CRP values by dividing them into the categories CRP 30, and, separately, according to short and long 5-year survival. The aim was to discover differentially expressed proteins associated with poor prognosis and shorter survival. We quantified 256 proteins and performed detailed statistical analyses and pathway analysis. We discovered multiple proteins that are up- or downregulated in patients with CRP >30 as compared to CRP <30 and in patients with short as compared to long 5-year survival. Pathways that were enriched include LXR/RXR activation, FXR/RXR activation, complement and coagulation cascades and acute phase signaling response, with some of the proteins we identified having roles in these pathways. In this study, we have identified multiple proteins, of which a few have been previously identified as potential biomarkers, and others that have been identified as potential biomarkers for CRC for the first time, to the best of our knowledge. While these proteins still need to be validated in larger patient series, this pilot study will pave the way for future studies aiming to provide better biomarkers for patients with CRC.Keywords
Funding Information
- Helsinki University Hospital
- Sigrid Juséliuksen Säätiö
- Syöpäjärjestöt
This publication has 53 references indexed in Scilit:
- Dysregulated lipid metabolism in cancerWorld Journal of Biological Chemistry, 2012
- Oxidized LDL Receptor 1 (OLR1) as a Possible Link between Obesity, Dyslipidemia and CancerPLOS ONE, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosisBritish Journal of Cancer, 2010
- Serum amyloid ACancer, 2009
- Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 2009
- Comparisons of methods for multiple hypothesis testing in neuropsychological research.Neuropsychology, 2009
- Identification of serum biomarkers for colon cancer by proteomic analysisBritish Journal of Cancer, 2006
- Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and CancerArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A proteinImmunology Today, 1994